Etiology and Treatment of Macular Edema

American Journal of Ophthalmology

Volumn 147, Issue 1, 2009, Pages

  Johnson, Mark W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; LASER COAGULATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA MACULA EDEMA; VITRECTOMY;

EID: 57549102804     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.07.024     Document Type: Article

References (61)

1. Tso M.O.M. Pathology of cystoid macular edema. Ophthalmology 89 (1982) 902-915
2. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., and Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80 (1996) 332-336
3. Tranos P.G., Wickremasinghe S.S., Stangos N.T., Topouzis F., Tsinopoulos I., and Pavesio C.E. Macular edema. Surv Ophthalmol 49 (2004) 470-490
4. Taylor H.R. LXIII Edward Jackson Memorial Lecture: Eye care: dollars and sense. Am J Ophthalmol 143 (2007) 1-8
5. Catier A., Tadayoni R., Paques M., et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 140 (2005) 200-206
6. Saishin Y., Saishin Y., Takahashi K., Melia M., Vinores S.A., and Campochiaro P.A. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 195 (2003) 210-219
7. Cordero Coma M., Sobrin L., Onal S., Christen W., and Foster C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114 (2007) 1574-1579
8. Leal E.C., Manivannan A., Hosoya K., et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 48 (2007) 5257-5265
9. Miyamoto K., Khosrof S., Bursell S.E., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96 (1999) 10836-10841
10. Kirber W.M., Nichols C.W., Grimes P.A., Winegrad A.I., and Laties A.M. A permeability defect of the retinal pigment epithelium. Occurrence in early streptozocin diabetes. Arch Ophthalmol 98 (1980) 725-728
11. Wright P.L., Wilkinson C.P., Balyeat H.D., Popham J., and Reinke M. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol 106 (1988) 740-744
12. Bucher R.S., Hall E., Reed D.M., Richards J.E., Johnson M.W., and Zacks D.N. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent responses to treatment. Arch Ophthalmol 123 (2005) 649-653
13. Zacks D.N., and Johnson M.W. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina 25 (2005) 135-140
14. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 97 (1999) 297-309
15. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
16. Jaffe G.J., Martin D., Callanan D., et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113 (2006) 1020-1027
17. Harbour J.W., Smiddy W.E., Rubsamen P.E., Murray T.G., Davis J.L., and Flynn Jr. H.W. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 120 (1995) 302-307
18. Antcliff R.J., and Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14 (1999) 223-232
19. Qaum T., Xu Q., Joussen A.M., et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42 (2001) 2408-2413
20. Joussen A.M., Smyth N., and Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol 39 (2007) 1-12
21. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 (2002) 2579-2588
22. Joussen A.M., Poulaki V., Le M.L., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18 (2004) 1450-1452
23. Miyamoto K., Khosrof S., Bursell S.E., et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156 (2000) 1733-1739
24. Lewis H., Abrams G.W., Blumenkranz M.S., and Campo R.V. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99 (1992) 753-759
25. Massin P., Duguid G., Erginay A., Haouchine B., and Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 135 (2003) 169-177
26. Gaucher D., Tadayoni R., Erginay A., Haouchine B., Gaudric A., and Massin P. Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol 139 (2005) 807-813
27. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol 103 (1985) 1796-1806
28. Mirza R.G., Johnson M.W., and Jampol L.M. Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. Surv Ophthalmol 52 (2007) 397-421
29. Harbour J.W., Smiddy W.E., Flynn H.W., and Rubsamen P.E. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 121 (1996) 405-413
30. Shah S.P., Patel M., Thomas D., Aldington S., and Laidlaw D.A. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol 90 (2006) 33-36
31. Tamura H., Miyamoto K., Kiryu J., et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46 (2005) 1440-1444
32. Gillies M.C., Sutter F.K.P., Simpson J.M., Larsson J., Ali H., and Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 113 (2006) 1533-1538
33. Cunningham Jr. E.T., Adamis A.P., Altaweel M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
34. Chun D.W., Heier J.S., Topping T.M., Duker J.S., and Bankert J.M. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113 (2006) 1706-1712
35. Nguyen Q.D., Tatlipinar S., Shah S.M., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006) 961-969
36. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
37. Kang S.W., Sa H.S., Cho H.Y., and Kim J.I. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 124 (2006) 653-658
38. Lam D.S.C., Chan C.K.M., Mohamed S., et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: Six month outcomes. Ophthalmology 114 (2007) 2162-2167
39. Finger P.T., and Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol 125 (2007) 751-756
40. Matsumoto Y., Freund K.B., Peiretti E., Cooney M.J., Ferrara D.C., and Yannuzzi L.A. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 27 (2007) 426-431
41. Nishijima K., Ng Y.S., Zhong L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171 (2007) 53-67
42. Thompson J.T. What is the role of vitrectomy for macular edema from branch retinal vein occlusion?. Am J Ophthalmol 138 (2004) 1037-1038
43. Samuel M.A., Equi R.A., Chang T.S., et al. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology 114 (2007) 1526-1529
44. Hee M.R., Baumal C.R., and Puliafito C.A. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 103 (1996) 1260-1270
45. Ting T.D., Oh M., Cox T.A., Meyer C., and Toth C.A. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol 120 (2002) 731-737
46. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
47. Krebs I., Stolba U., Glittenberg C., Seyeddain O., Benesch T., and Binder S. Prognosis of untreated occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 245 (2007) 376-384
48. Moroi S.E., Gottfredsdottir M.S., Schteingart M.T., et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 106 (1999) 1024-1029
49. Telander D.G., and Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22 (2007) 151-153
50. Joshi M.M., and Garretson B.R. Paclitaxel maculopathy. Arch Ophthalmol 125 (2007) 709-710
51. Ryan Jr. E.H., Han D.P., Ramsay R.C., et al. Diabetic macular edema associated with glitazone use. Retina 26 (2006) 562-570
52. Scorolli L., Morara M., Meduri A., et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 125 (2007) 759-764
53. Heckenlively J.R., Jordan B.L., and Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127 (1999) 565-573
54. Johnson M.W. Tractional cystoid macular edema: A subtle variant of the vitreomacular traction syndrome. Am J Ophthalmol 140 (2005) 184-192
55. Benhamou N., Massin P., Haouchine B., Erginay A., and Gaudric A. Macular retinoschisis in highly myopic eyes. Am J Ophthalmol 133 (2002) 794-800
56. Panozzo G., and Mercanti A. Vitrectomy for myopic traction maculopathy. Arch Ophthalmol 125 (2007) 767-772
57. Porrini G., Giovannini A., Amato G., Ioni A., and Pantanetti M. Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology 110 (2003) 674-680
58. Girmens J.F., Erginay A., Massin P., Scigalla P., Gaudric A., and Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 136 (2003) 194-196
59. Brodsky M.C. Congenital optic disk anomalies. Surv Ophthalmol 39 (1994) 89-112
60. Lincoff H., Lopez R., Kreissig I., et al. Retinoschisis associated with optic nerve pits. Arch Ophthalmol 106 (1988) 61-67
61. Johnson T.M., and Johnson M.W. Pathogenic implications of subretinal gas migration through pits and atypical colobomas of the optic nerve. Arch Ophthalmol 122 (2004) 1793-1800